Patents by Inventor Tomokazu Matsusue

Tomokazu Matsusue has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-PLATELET MEMBRANE GLYCOPROTEIN VI MONOCLONAL ANTIBODY
    Publication number: 20140044723
    Abstract: The present invention provides an antibody which has the following features, its active fragment, or a derivative thereof: a) It specifically binds to human platelet membrane glycoprotein VI (GPVI); b) The function to activate a platelet and/or the function to induce a thrombocytopenia in vivo are low; and c) It at least partially depletes GPVI on the platelet membrane by contacting with a platelet.
    Type: Application
    Filed: July 24, 2013
    Publication date: February 13, 2014
    Inventors: Hiroshi Takayama, Kamon Shirakawa, Shoji Furusako, Yoshitaka Hosaka, Tomokazu Matsusue, Katsuki Naitoh, Yumi Hotta, Tetsushi Kawahara, Motoyasu Honda
  • Anti-platelet membrane glycoprotein VI monoclonal antibody
    Patent number: 8524870
    Abstract: The present invention provides an antibody which has the following features, its active fragment, or a derivative thereof: a) It specifically binds to human platelet membrane glycoprotein VI (GPVI); b) The function to activate a platelet and/or the function to induce a thrombocytopenia in vivo are low; and c) It at least partially depletes GPVI on the platelet membrane by contacting with a platelet.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: September 3, 2013
    Assignee: Mochida Pharmaceutical Co., Ltd.
    Inventors: Hiroshi Takayama, Kamon Shirakawa, Shoji Furusako, Yoshitaka Hosaka, Tomokazu Matsusue, Katsuki Naitoh, Yumi Hotta, Tetsushi Kawahara, Motoyasu Honda
  • Anti-platelet membrane glycoprotein VI monoclonal antibody
    Patent number: 8389692
    Abstract: The present invention provides an antibody which has the following features, its active fragment, or a derivative thereof: a) It specifically binds to human platelet membrane glycoprotein VI (GPVI); b) The function to activate a platelet and/or the function to induce a thrombocytopenia in vivo are low; and c) It at least partially depletes GPVI on the platelet membrane by contacting with a platelet.
    Type: Grant
    Filed: April 27, 2011
    Date of Patent: March 5, 2013
    Assignee: Mochida Pharmaceutical Co., Ltd.
    Inventors: Hiroshi Takayama, Kamon Shirakawa, Shoji Furusako, Yoshitaka Hosaka, Tomokazu Matsusue, Katsuki Naitoh, Yumi Hotta, Tetsushi Kawahara, Motoyasu Honda
  • ANTI-PLATELET MEMBRANE GLYCOPROTEIN VI MONOCLONAL ANTIBODY
    Publication number: 20110217318
    Abstract: The present invention provides an antibody which has the following features, its active fragment, or a derivative thereof: a) It specifically binds to human platelet membrane glycoprotein VI (GPVI); b) The function to activate a platelet and/or the function to induce a thrombocytopenia in vivo are low; and c) It at least partially depletes GPVI on the platelet membrane by contacting with a platelet.
    Type: Application
    Filed: April 27, 2011
    Publication date: September 8, 2011
    Inventors: HIROSHI TAKAYAMA, KAMON SHIRAKAWA, SHOJI FURUSAKO, YOSHITAKA HOSAKA, TOMOKAZU MATSUSUE, KATSUKI NAITOH, YUMI HOTTA, TETSUSHI KAWAHARA, MOTOYASU HONDA
  • Anti-platelet membrane glycoprotein VI monoclonal antibody
    Patent number: 7977461
    Abstract: The present invention provides an antibody which has the following features, its active fragment, or a derivative thereof: a) It specifically binds to human platelet membrane glycoprotein VI (GPVI); b) The function to activate a platelet and/or the function to induce a thrombocytopenia in vivo are low; and c) It at least partially depletes GPVI on the platelet membrane by contacting with a platelet.
    Type: Grant
    Filed: April 28, 2006
    Date of Patent: July 12, 2011
    Assignee: Mochida Pharmaceutical Co., Ltd.
    Inventors: Hiroshi Takayama, Kamon Shirakawa, Shoji Furusako, Yoshitaka Hosaka, Tomokazu Matsusue, Katsuki Naitoh, Yumi Hotta, Tetsushi Kawahara, Motoyasu Honda
  • ANTI-PLATELET MEMBRANE GLYCOPROTEIN VI MONOCLONAL ANTIBODY
    Publication number: 20090092612
    Abstract: The present invention provides an antibody which has the following features, its active fragment, or a derivative thereof: a) It specifically binds to human platelet membrane glycoprotein VI (GPVI); b) The function to activate a platelet and/or the function to induce a thrombocytopenia in vivo are low; and c) It at least partially depletes GPVI on the platelet membrane by contacting with a platelet.
    Type: Application
    Filed: April 28, 2006
    Publication date: April 9, 2009
    Inventors: Hiroshi Takayama, Kamon Shirakawa, Shoji Furusako, Yoshitaka Hosaka, Tomokazu Matsusue, Katsuki Naitoh, Yumi Hotta, Tetsushi Kawahara, Motoyasu Honda
  • ANTI-PLATELET MEMBRANE GLYCOPROTEIN VI MONOCLONAL ANTIBODY
    Publication number: 20090041783
    Abstract: The present invention provides an antibody which has the following features, its active fragment, or a derivative thereof: a) It specifically binds to human platelet membrane glycoprotein VI (GPVI); b) The function to activate a platelet and/or the function to induce a thrombocytopenia in vivo are low; and c) It at least partially depletes GPVI on the platelet membrane by contacting with a platelet.
    Type: Application
    Filed: January 27, 2006
    Publication date: February 12, 2009
    Inventors: Hiroshi Takayama, Kamon Shirakawa, Shoji Furusako, Yoshitaka Hosaka, Tomokazu Matsusue, Katsuki Naitoh, Yumi Hotta, Tetsushi Kawahara
  • Egf/egfr complex
    Publication number: 20070032637
    Abstract: The present invention relates to a crystal of a complex of an epidermal growth factor (EGF) and an epidermal growth factor receptor (EGFR), a crystal of a complex of EGFR and a substance regulating EGFR activity, structure coordinates of these crystals, a method for screening for the substance regulating EGFR activity, a method for designing the substance regulating EGFR activity, a method for designing an EGFR variant or an EGF variant, a method for producing an EGFR variant or an EGF variant and an EGF variant or an EGFR variant obtainable by such method, a method for designing an epitope using the structure coordinates of the EGF-EGFR complex, a method for producing an anti-EGFR antibody or an anti-EGF antibody and an antibody obtainable by such method, a polypeptide or a salt thereof comprising a region that forms an EGFR dimerization site, and the like.
    Type: Application
    Filed: September 12, 2002
    Publication date: February 8, 2007
    Applicant: JAPAN SCIENCE AND TECHNOLOGY AGENCY
    Inventors: Shigeyuki Yokoyama, Hideo Ogiso, Mikako Shirouzu, Osamu Nureki, Ryuichiro Ishitani, Kazuki Saito, Tomokazu Matsusue, Naoki Nakao, Hiroyuki Muramatsu, Mikihiko Shinozaki
  • Anti-Fas ligand antibody and assay method using the anti-Fas ligand antibody
    Patent number: 6114507
    Abstract: An anti-Fas ligand antibody capable of suppressing Fas ligand-induced apoptosis to a high degree, especially humanized antibodies having less antigenecity to human, and a method for assaying the Fas ligand in human body fluid utilizing such an antibody.Measurement of the Fas ligand in human body fluid would be useful for elucidation of hepatitis B, hepatitis C, HIV infections and the like, and for prediction and diagnosis of pathological conditions associated with such diseases.
    Type: Grant
    Filed: May 17, 1996
    Date of Patent: September 5, 2000
    Assignees: Mochida Pharmaceutical Co., Ltd., Osaka Bioscience Institute
    Inventors: Kamon Shirakawa, Tomokazu Matsusue, Shigekazu Nagata, Man Sung Co, Maximiliano Vasquez
  • Agent for suppressing a reduction of CD4.sup.+ lymphocytes
    Patent number: 6096312
    Abstract: An agent for preventing or treating AIDS which contains as its effective component an anti-Fas ligand antibody, and the method for preventing and treating AIDS by using such drug.
    Type: Grant
    Filed: January 22, 1998
    Date of Patent: August 1, 2000
    Assignees: Mochida Pharmaceutical Co., Ltd., Osaka Bioscience Institute
    Inventors: Norio Nakamura, Kamon Shirakawa, Tomokazu Matsusue, Shigekazu Nagata, Man Sung Co, Maximiliano Vasquez